Ulcerative colitis clinical trials have expanded dramatically over the past decade, testing a growing range of biologics, small molecules, and even microbiome-based therapies against increasingly sophisticated measures of disease control. Where earlier trials focused on whether patients felt better and whether their symptoms eased, modern studies ask harder questions: has the visible inflammation in the colon actually healed, and does the tissue look normal under a microscope? That shift in what counts as success has changed how drugs are developed, compared, and approved for the roughly one million people in the United States living with this disease.
How Trial Success Is Measured
If you have followed ulcerative colitis research even casually, you have probably encountered the term “clinical remission.” In most trials, that means a patient’s combined symptom score has dropped to near zero, with no significant rectal bleeding and close-to-normal stool frequency. But the field has been steadily raising the bar beyond symptom control alone.
Endoscopic improvement, confirmed by a gastroenterologist reviewing images of the colon lining, is now a standard co-primary endpoint. A healed-looking colon predicts better long-term outcomes than symptom relief alone. And layered on top of that is histologic remission, where a biopsy of the tissue shows no residual inflammation under a microscope. Achieving histologic remission has been linked to lower rates of relapse, hospitalization, colectomy, and colorectal cancer.1PubMed. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials Despite that promise, histologic remission remains somewhat controversial as a formal treatment target. A consensus initiative called STRIDE labeled it a goal to “consider but not a formal target,” partly because different scoring systems define it differently and not all studies agree on how reliably it predicts outcomes.2Inflammatory Intestinal Diseases. Mucosal Healing of Ulcerative Colitis Based on Endoscopic Diagnosis, Histopathology, and Mucosal Inflammatory Mediators
The practical importance of combining these endpoints showed up clearly in the ustekinumab trials. Patients who achieved both histologic and endoscopic improvement after induction had roughly 10 to 20 percent higher rates of sustained remission at week 44 compared with patients who had improvement on only one measure.3PubMed. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis That gap is meaningful enough that regulators are now paying close attention to whether new drugs can clear both hurdles.
Patient-Reported Endpoints Are Getting More Specific
Traditional symptom scores capture stool frequency and bleeding, but they miss one of the symptoms patients care about most: bowel urgency. That desperate, can’t-wait sensation affects everything from commuting to socializing, and until recently it had no standardized way of being measured in a trial. A tool called the Urgency Numeric Rating Scale (Urgency NRS), where patients rate urgency from 0 to 10, has now been psychometrically validated and is being incorporated into clinical trials as a recognized endpoint.4PubMed Central. Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis 5Journal of Crohn’s and Colitis. P138 Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe Ulcerative Colitis Including urgency as a trial endpoint aligns what researchers measure with what patients actually want fixed.
The Biologic Therapies That Shaped Modern Trials
The first wave of biologic trials in ulcerative colitis centered on anti-TNF agents, drugs that block tumor necrosis factor, a protein that drives inflammation. The landmark ACT 1 and ACT 2 trials in 2005 tested infliximab in patients with moderate-to-severe disease who had not responded to steroids or other standard treatments. At eight weeks, about two-thirds of infliximab-treated patients showed a clinical response, compared with roughly a third on placebo.6Gut and Liver. Current and Emerging Biologics for Ulcerative Colitis Those trials established the template that nearly every subsequent ulcerative colitis study has followed: induction with a loading dose, then maintenance dosing, measuring response, remission, and mucosal healing at defined intervals.
One persistent challenge with anti-TNF drugs is that about 40 percent of patients eventually lose response to them. The suspected reasons include the body producing antibodies against the drug itself and increased drug clearance over time.7Gut and Liver. Current and Emerging Biologics for Ulcerative Colitis Combining an anti-TNF agent with an immunomodulator has been shown to work better than using the biologic alone, and dose intensification can help patients who start losing response.8PubMed Central. Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
A second class of biologics targets gut-specific immune trafficking rather than TNF. Vedolizumab, a gut-selective drug that blocks a protein called α4β7 integrin, prevents certain immune cells from migrating into inflamed colon tissue.9PubMed Central. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease Its pivotal trials showed it could induce and maintain remission, and a subsequent head-to-head trial called VARSITY compared it directly against adalimumab, an anti-TNF therapy. At one year, vedolizumab produced clinical remission in about 31 percent of patients versus roughly 23 percent on adalimumab, and endoscopic improvement was also significantly higher with vedolizumab.10PubMed. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis VARSITY was a landmark because head-to-head biologic comparisons in ulcerative colitis had been essentially nonexistent before it; most drugs were tested only against placebo.11PubMed Central. Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
More recently, a newer class targeting the cytokine IL-23 has entered the picture. Multiple IL-23 inhibitors have now shown significant efficacy in both inducing and maintaining remission, with favorable safety profiles across randomized controlled trials.12PubMed Central. Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials These drugs work for patients who have already failed other biologics, which is especially valuable because the treatment-refractory population keeps growing as more patients cycle through available options.13PubMed. Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis
Small Molecules and Oral Options
Not every patient wants or can tolerate infusions or injections, and small-molecule oral therapies have opened up a different lane in trials. Tofacitinib, a JAK inhibitor taken by mouth, was the first in this class approved for ulcerative colitis. Safety data from over four years of global trial experience showed that the main signal to watch was herpes zoster (shingles), which occurred at a higher rate in the 10 mg twice-daily group than with placebo. Rates of serious infections, cardiovascular events, and malignancies were generally low across all dosing groups.14Clinical Gastroenterology and Hepatology. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
Another class of oral therapies modulates S1P receptors, which control how immune cells exit lymph nodes and enter the bloodstream. By keeping certain immune cells trapped in the lymph nodes rather than letting them travel to the inflamed colon, these drugs reduce inflammation through a mechanism entirely different from biologics or other JAK inhibitors.15PubMed Central. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis Having multiple distinct mechanisms available matters for trial design because each new drug can be tested in patients who have failed the others.
The Placebo Problem
One of the trickiest aspects of designing ulcerative colitis trials is dealing with the placebo response, where a meaningful percentage of patients receiving an inactive treatment still improve. A systematic review and meta-analysis of induction and maintenance trials found that placebo remission rates vary considerably and are influenced by several factors. Patients who had already failed a biologic tended to have lower placebo response rates, as did patients with more severe endoscopic disease at baseline. On the other hand, more frequent follow-up visits and longer trial durations were associated with higher clinical placebo rates, and the absence of centralized endoscopy reading inflated apparent placebo endoscopic improvement.16Journal of Crohn’s and Colitis. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis
A pooled patient-level analysis dug deeper into which individual characteristics predicted placebo response. Patients with normal inflammatory markers (CRP and albumin) were more than twice as likely to achieve a clinical response on placebo compared with patients who had abnormal markers, which makes sense: those patients may have had milder underlying disease from the start. Patients with the most severe endoscopic scores were less likely to respond to placebo.17Clinical Gastroenterology and Hepatology. Factors Associated With Placebo Response and Remission in Clinical Trials of Ulcerative Colitis: A Pooled Patient-Level Analysis Understanding these patterns helps trialists design studies that can detect a real drug effect without it being washed out by a high placebo rate.
How AI Is Changing Trial Readouts
Endoscopic scoring in a clinical trial has traditionally required trained central readers to watch colonoscopy videos and assign standardized grades. That process is expensive, slow, and still somewhat subjective. Several research groups have now built deep-learning models that can grade endoscopy videos automatically. One neural network model trained on data from multicenter trials achieved excellent agreement with human central readers for both the Mayo endoscopic subscore and another standardized index called the UCEIS.18PubMed. Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks
A newer approach goes even further by fusing endoscopic video with histologic whole-slide images into a single multimodal AI model. Tested on data from a Phase 2 trial, this fusion model outperformed single-modality assessments for histologic remission, reaching about 90 percent accuracy in predicting whether a patient had achieved remission.19Journal of Crohn’s and Colitis. Endo-Histo foundational fusion model: a novel artificial intelligence for assessing histologic remission and response to therapy in ulcerative colitis clinical trial If tools like these are eventually validated broadly enough for regulatory acceptance, they could standardize scoring across trial sites and dramatically speed up how quickly results are read.
Fecal Microbiota Transplant and Microbiome-Based Approaches
The idea of transplanting a healthy donor’s gut bacteria into an inflamed colon has been tested in several randomized trials. In one such trial, about a third of patients receiving donor fecal microbiota transplant (FMT) achieved steroid-free remission at eight weeks, compared with roughly 9 percent receiving a control transplant from their own stool. Clinical response was also markedly higher in the donor FMT group.20JAMA. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial
An interesting wrinkle is that FMT outcomes appear to depend heavily on which donor’s material is used. A more recent trial found that clinical response and the durability of microbiome shifts after FMT were donor-dependent, with certain donors’ bacterial strains engrafting far more successfully than others.21PubMed Central. Donor composition and fiber promote strain engraftment in a randomized controlled trial of fecal microbiota transplant for ulcerative colitis That finding suggests FMT might need to be personalized or at least donor-optimized before it could become a mainstream treatment, and it partly explains why results have been inconsistent across trials.
Combination and Dual-Targeted Therapy
For patients who do not respond adequately to a single advanced therapy, researchers are testing the idea of combining two drugs with different mechanisms. A proof-of-concept trial called VEGA tested the combination of guselkumab (an IL-23 inhibitor) plus golimumab (an anti-TNF agent) against either drug alone. At 12 weeks, about 83 percent of patients on the combination achieved a clinical response, compared with 61 percent on golimumab alone and 75 percent on guselkumab alone.22The Lancet Gastroenterology & Hepatology. Efficacy and safety of guselkumab plus golimumab combination therapy versus golimumab or guselkumab monotherapy in patients with moderately-to-severely active ulcerative colitis (VEGA)
Outside of controlled trials, retrospective data on dual-targeted therapy, most commonly a biologic paired with a JAK inhibitor, have also looked encouraging. In one study of 42 ulcerative colitis patients receiving dual-targeted therapy, endoscopic improvement was documented in about 69 percent of cases with matched before-and-after samples, and about 73 percent of patients reported clinical improvement. The most common side effects were upper respiratory infections and skin issues, with no blood clots reported.23Crohn’s & Colitis 360. Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease: A Retrospective Study Larger, controlled trials of combination strategies are now underway, including master protocol designs that allow multiple drug combinations to be evaluated under one shared framework.24TrialX. A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn’s Disease
Using Biomarkers to Guide Treatment During Trials
Treat-to-target strategies rely on objective markers to decide whether a therapy is working rather than waiting for symptoms to worsen. Fecal calprotectin, a protein shed by inflamed gut tissue and measurable in a stool sample, has emerged as one of the most practical monitoring tools. In a study using data from large biologic trials, a post-induction fecal calprotectin level at or below 250 μg/g was associated with roughly four to six times higher odds of achieving clinical, endoscopic, and histologic remission at one year. The same threshold also predicted lower rates of colectomy over seven years and fewer ulcerative-colitis-related hospitalizations.25Clinical Gastroenterology and Hepatology. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis A cheap stool test predicting outcomes years into the future is the kind of tool that makes adaptive trial designs and real-world monitoring far more feasible.
Real-World Data Versus Trial Results
Controlled trials use strict enrollment criteria, close monitoring, and frequent visits, all of which can make drugs look either better or worse than they perform in everyday clinical care. A large systematic review of real-world studies found that clinical remission rates varied widely across therapies and settings. Vedolizumab had the most published real-world evidence, followed by tofacitinib and adalimumab. Comparative effectiveness studies generally confirmed what VARSITY showed: vedolizumab tended to produce numerically higher clinical remission rates than anti-TNF agents. However, tofacitinib sometimes outperformed vedolizumab in real-world remission rates, a finding that occasionally reached statistical significance.26PubMed Central. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review That real-world tofacitinib signal is worth watching, since no head-to-head randomized trial has yet compared it to vedolizumab.
Who Gets Left Out of Trials
The evidence base for ulcerative colitis therapies is disproportionately built on data from white patients. An analysis of randomized trials for inflammatory bowel disease found that almost 40 percent of studies did not report participants’ race at all, and another 23 percent reported only the proportion of white participants without any further breakdown. Participation by Black and Hispanic patients was very low relative to the rising incidence of IBD in those populations.27PubMed Central. Inclusion of Under-Represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease A focused review of ulcerative colitis drug-development trials specifically found that among the minority of studies that reported race, about 86 percent of enrolled patients were white. Only about 3 percent were Black.28Inflammatory Bowel Diseases. Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials
This is not just an ethical concern. Drug metabolism, disease behavior, and treatment response can vary across populations. If the data informing prescribing decisions comes almost entirely from one demographic group, clinicians have less confidence about how a drug will perform for everyone else.
Children and the Approval Gap
Pediatric patients face a different but related problem. Most ulcerative colitis drugs are approved first in adults, and the path to pediatric approval is slow and sometimes unnecessarily burdensome. A recent commentary argued that the FDA has been willing to extrapolate efficacy from adult data for children with rheumatologic conditions but has held pediatric IBD to a stricter standard, requiring full efficacy trials even when pharmacokinetic and pharmacodynamic studies could have sufficed. The result is years of delay during which children with severe disease can only access these drugs off-label.29PubMed Central. Children With Inflammatory Bowel Diseases are Disadvantaged by Current Drug Approval Policies: A Call for Urgent Change For families managing a child’s ulcerative colitis, the gap between when an effective drug is proven in adults and when it becomes officially available for pediatric use is a source of real frustration.
Stem Cell Therapy in Early Trials
Mesenchymal stem cells, harvested from bone marrow or umbilical cord tissue, have immunomodulatory properties that make them theoretically attractive for autoimmune conditions like ulcerative colitis. A systematic review combining animal and human data found that stem cell therapy elevated healing rates compared with standard treatment.30PubMed Central. Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies One study of 41 patients receiving umbilical-cord-derived stem cell therapy reported a clinical response rate of about 73 percent at two months and roughly 70 percent at six months.31PubMed Central. Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms A separate early-phase trial using bone-marrow-derived stem cells found endoscopic improvement in all four treated patients by two weeks, though sample sizes this small can only hint at a signal.32PubMed Central. A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis Stem cell therapy for ulcerative colitis is genuinely early-stage. The results so far are intriguing but far from the large, rigorous trials needed for regulatory approval, and practical questions about dosing, delivery route, and long-term safety remain wide open.